NO20053125L - Rekombinant koppevirus omfattende i det minste to kukoppe-ati-promotere. - Google Patents

Rekombinant koppevirus omfattende i det minste to kukoppe-ati-promotere.

Info

Publication number
NO20053125L
NO20053125L NO20053125A NO20053125A NO20053125L NO 20053125 L NO20053125 L NO 20053125L NO 20053125 A NO20053125 A NO 20053125A NO 20053125 A NO20053125 A NO 20053125A NO 20053125 L NO20053125 L NO 20053125L
Authority
NO
Norway
Prior art keywords
smallpox
recombinant
seq
ati
virus
Prior art date
Application number
NO20053125A
Other languages
English (en)
Other versions
NO20053125D0 (no
Inventor
Paul Howley
Sonja Leyrer
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of NO20053125D0 publication Critical patent/NO20053125D0/no
Publication of NO20053125L publication Critical patent/NO20053125L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Oppfinnelsen angår rekombinante koppevirus omfattende i det virale genomet i det minste to ekspresjonskassetter, hver omfattende kukoppe-ATI-promotere eller et derivat derav og en kodende sekvens hvor ekspresjonen av den kodende sekvensen reguleres av nevnte promoter. Viruset kan anvendes som en vaksine eller som en del av et farmasøytisk preparat.
NO20053125A 2002-11-25 2005-06-24 Rekombinant koppevirus omfattende i det minste to kukoppe-ati-promotere. NO20053125L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200201814 2002-11-25
PCT/EP2003/012610 WO2004048582A2 (en) 2002-11-25 2003-11-12 Recombinant poxvirus comprising at least two cowpox ati promoters

Publications (2)

Publication Number Publication Date
NO20053125D0 NO20053125D0 (no) 2005-06-24
NO20053125L true NO20053125L (no) 2005-06-24

Family

ID=32337938

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053125A NO20053125L (no) 2002-11-25 2005-06-24 Rekombinant koppevirus omfattende i det minste to kukoppe-ati-promotere.

Country Status (21)

Country Link
US (1) US7300658B2 (no)
EP (1) EP1567653B1 (no)
JP (1) JP2006515170A (no)
KR (1) KR20050083839A (no)
CN (1) CN1717488A (no)
AT (1) ATE365220T1 (no)
AU (1) AU2003293675B2 (no)
CA (1) CA2501168A1 (no)
CY (1) CY1106883T1 (no)
DE (1) DE60314541T2 (no)
DK (1) DK1567653T3 (no)
EA (1) EA012723B1 (no)
ES (1) ES2288634T3 (no)
IL (1) IL167844A (no)
MX (1) MXPA05005549A (no)
NO (1) NO20053125L (no)
NZ (1) NZ540156A (no)
PL (1) PL375740A1 (no)
PT (1) PT1567653E (no)
UA (1) UA85379C2 (no)
WO (1) WO2004048582A2 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100537773C (zh) * 2000-11-23 2009-09-09 巴法里安诺迪克有限公司 改良安卡拉痘苗病毒变体
JP4895505B2 (ja) * 2002-05-16 2012-03-14 バヴァリアン・ノルディック・アクティーゼルスカブ 変異ワクシニアウイルスアンカラ（ｍｖａ）ゲノム中の挿入部位としての遺伝子間領域
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
EP2426142A3 (en) * 2006-10-16 2012-06-13 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
WO2009152969A1 (en) * 2008-06-20 2009-12-23 Bavarian Nordic A/S Recombinant modified vaccinia virus measles vaccine
CA2742247C (en) 2008-11-21 2017-07-04 Bavarian Nordic A/S Vector comprising multiple homologous nucleotide sequences
US8394385B2 (en) * 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
WO2013115884A2 (en) * 2011-11-15 2013-08-08 Trustees Of Boston University Pyridopyrimidinone inhibitors of viruses
WO2016115116A1 (en) 2015-01-12 2016-07-21 Geovax, Inc. Compositions and methods for generating an immune response to a hemorrhagic fever virus
KR20160140075A (ko) 2015-05-29 2016-12-07 코오롱생명과학 주식회사 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
RU2752498C2 (ru) * 2015-11-24 2021-07-28 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Стабильные клеточные линии для продуцирования ретровирусов
FR3044017B1 (fr) * 2015-11-24 2019-05-03 Glaxosmithkline Intellectual Property Development Limited Procede de transfection transitoire pour la production retrovirale
ES2944314T3 (es) 2016-01-08 2023-06-20 Geovax Inc Composiciones y procedimientos para generar una respuesta inmunitaria frente a un antígeno asociado a un tumor
US20190030157A1 (en) 2016-02-03 2019-01-31 Geovax Inc. Compositions and Methods for Generating an Immune Response to a Flavivirus
KR20230113832A (ko) * 2016-08-09 2023-08-01 시티 오브 호프 키메라 폭스바이러스 조성물 및 이의 용도
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443964A (en) * 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
US5759841A (en) * 1990-11-20 1998-06-02 Virogenetics Corporation Immunological composition of measles virus utilizing recombinant poxvirus
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
ID19548A (id) * 1996-09-24 1998-07-23 Bavarian Nordic Res Inst As Virus mva rekombinan yang mengekspresikan antigen-antigen virus demam dan penggunaan daripadanya dalam vaksin-vaksin
DK1180155T3 (da) * 1999-05-28 2009-02-16 Helmholtz Zentrum Muenchen Vektor til integration af heterologe sekvenser i poxvirale genomer
DE60130569D1 (de) * 2000-08-29 2007-10-31 Wyeth Corp Verpackung von replikon-partikeln eines positiv-strängigen rna-virus

Also Published As

Publication number Publication date
DK1567653T3 (da) 2007-10-15
AU2003293675B2 (en) 2009-04-23
CA2501168A1 (en) 2004-06-10
ATE365220T1 (de) 2007-07-15
AU2003293675A1 (en) 2004-06-18
DE60314541D1 (de) 2007-08-02
PL375740A1 (en) 2005-12-12
EA012723B1 (ru) 2009-12-30
NO20053125D0 (no) 2005-06-24
WO2004048582A2 (en) 2004-06-10
US20060153874A1 (en) 2006-07-13
PT1567653E (pt) 2007-10-01
ES2288634T3 (es) 2008-01-16
JP2006515170A (ja) 2006-05-25
WO2004048582A3 (en) 2004-08-12
IL167844A (en) 2011-03-31
CY1106883T1 (el) 2012-09-26
NZ540156A (en) 2006-11-30
EP1567653B1 (en) 2007-06-20
MXPA05005549A (es) 2005-08-16
DE60314541T2 (de) 2008-02-28
EA200500879A1 (ru) 2005-10-27
KR20050083839A (ko) 2005-08-26
EP1567653A2 (en) 2005-08-31
CN1717488A (zh) 2006-01-04
US7300658B2 (en) 2007-11-27
UA85379C2 (ru) 2009-01-26

Similar Documents

Publication Publication Date Title
NO20053125L (no) Rekombinant koppevirus omfattende i det minste to kukoppe-ati-promotere.
HK1076835A1 (en) Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
UA82998C2 (ru) Экспрессия генов в модифицированном вирусе коровьей оспы ankara с использованием коровьего поксвирусного промотора аті
RU98101904A (ru) Рекомбинантный вирус mva и его использование
IL204539A (en) Foxvirus virus containing defective genes and a losing gene
MXPA02011545A (es) Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.
JP5952112B2 (ja) ポックスウイルスまたは他の感染性因子に対する免疫の急速な誘導に改変ポックスウイルスを使用する方法
WO1998013500A2 (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
CN101142319B (zh) 基于使用修饰安卡拉痘苗病毒的疫苗
AU2002337083A1 (en) Vaccinia virus mva-e3l-knockout-mutants and use thereof
UA84667C2 (ru) Вакцина, направленная против инфекции, вызванной вирусом герпеса болезни марека
CA2372709A1 (en) Vector for integration of heterologous sequences into poxviral genomes
HK1055762A1 (en) Generation of human cytomegalovirus yeast artificial chromosome recombinants
CA2430115A1 (en) Recombinant rsv virus expression systems and vaccines
NZ512341A (en) Polynucleotides between 15 and 100 base pairs in length coding for parapoxvirus ovis (PPVO)/vaccinia virus recombinant (VVOV) viral genome fragments
JP2009232836A5 (no)
CA2562136A1 (en) Novel infectious bursal disease virus and vaccine containing said virus
BR0316553A (pt) Poxvìrus recombinante que compreende pelo menos dois promotores ati de varìola bovina
DK200201813A (da) Ekspression af gener i modificeret vaccinia virus ankara ved brug af ATI promotoren fra ko-kopper
Cheng et al. 106 Gln Glu Glu 122 Met Met Val

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application